The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care

References

• American Diabetes Association. Treatment of hypertension in adults with diabetes. Position statement. Diabetes Care 2003;26:80S–82
   Google Scholar
• Sharma A, Wittchen H, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross sectional study. J Hypertens 2004;22:479–486
   PubMed Web of Science ®Google Scholar
• Pittrow D, Wittchen H, Kirch W. Hypertension and diabetes care among primary care doctors in Germany: results from an epidemiological cross-sectional study. In: Kirch W, ed. Public Health in Europe. Berlin, New York: Springer, 2003:203–218
   Google Scholar
• Epstein M, Sowers J. Diabetes mellitus and hypertension. Hypertension 1992;19:403–418
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Diabetes and hypertension. Diabetes Care 2001;24:1679–1684
   PubMed Web of Science ®Google Scholar
• Guidelines committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011–1053
   PubMed Web of Science ®Google Scholar
• Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617–621
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751–6
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998;317: 703–13
   Google Scholar
• Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138:593–602
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127: 788–95
   Google Scholar
• Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60:135–142
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hyper-tension. J Hypertens 2003;21: 1011–1053
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Ass 2003;289:2560–2571
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Hypertension in people with type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 2003;20:972–87
   PubMed Web of Science ®Google Scholar
• Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64:999–1028
   PubMed Web of Science ®Google Scholar
• Wagner N, Pittrow D, Kirch W, et al. The use of guidelines in the primary care management of hypertension and diabetes [German]. Soz Praventivmed 2004;49:261–268
   PubMedGoogle Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003
   PubMed Web of Science ®Google Scholar
• SAS. Cary NC: SAS Institute Inc., 1999
   Google Scholar
• Lehnert H, Bramlage P, Pittrow D, Kirch W. Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment. An observational study in 38 016 patients in primary care. Clin Drug Inv 2004;24:217–225
   Google Scholar
• Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Brit Med J 2000;321:412–9
   PubMed Web of Science ®Google Scholar
• Holzgreve H, Middeke M. Risk-benefit aspects of antihypertensive drugs. Drugs 1992;44(Suppl 1):67–73
   PubMedGoogle Scholar
• Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000;160:2447–2452
   Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870–878
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: 765–74
   Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887–1892
   Google Scholar